Table 2.
MTBDR plus Assay Results
| All (N = 353) | New PTB Patients (n = 149) (42.2%) | Previously Treated PTB Patients (n = 193) (54.7%) | Patients With Unknown PTB History (n = 11) (3.2%) | Smear-positive Patient Specimens | Smear-negative Patient Specimens | |
|---|---|---|---|---|---|---|
| Specimens with positive MTBDRplus results | ||||||
| RIFS-INHS | 117 (33.1) | 46 (30.9) | 65 (33.7) | 6 (54.5) | 101 (86.3) | 16 (13.7) |
| RIFS-INHR | 11 (3.1) | 6 (4) | 5 (2.6) | 0 | 11 (100) | 0 |
| RIFR-INHS | 34 (9.6) | 15 (10.1) | 19 (9.8) | 0 | 31 (91.2) | 3 (8.8) |
| RIFR-INHInd | 9 (2.6) | 3 (2) | 6 (3.1) | 0 | 9 (100) | 0 |
| RIFR-INHR | 53 (15) | 12 (8.1) | 41 (21.2) | 0 | 49 (92.5) | 4 (7.5) |
| Subtotal | 224 (63.5) | 82 (36.6) | 136 (60.7) | 6 (2.7) | 201 (89.7) | 23 (10.3) |
| Specimens with negative, invalid, or indeterminate MTBDRplus results | ||||||
| Negative | 99 (76.7) | 50 (50.5) | 34 (34.3) | 15 (15.2) | 81 (81.8) | 18 (18.2) |
| Invalid | 22 (17) | 6 (27.3) | 16 (72.7) | 0 | 21 (95.5) | 1 (4.5) |
| Indeterminate | 8 (6.3) | 1 (12.5) | 7 (87.5) | 0 | 8 (100) | 0 |
| Subtotal | 129 (36.5) | 57 (44.2) | 57 (44.2) | 15 (11.6) | 110 (85.3) | 19 (14.7) |
Data are presented as n (%).
Abbreviations: INHInd, isoniazid indeterminate; INHR, isoniazid resistant; INHS, isoniazid susceptible; PTB, pulmonary tuberculosis; RIFR, rifampicin resistant; RIFS, rifampicin susceptible.